Amphia Ziekenhuis

The trials here

What the 37 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer7 trials
• Coronary artery disease6 trials
• Heart failure5 trials
• Lung cancer4 trials
• Bladder cancer2 trials
• COPD2 trials
• Obesity2 trials
• Aortic stenosis1 trial
• Atrial fibrillation1 trial
• Childhood cancers1 trial
• Chronic lymphocytic leukaemia1 trial
• Gastric and oesophageal cancer1 trial
• and 8 more

Phase

• Phase 314 trials
• Phase 23 trials
• Phase 42 trials

Status

• Recruiting15 trials
• Completed12 trials
• Active, not recruiting8 trials
• Not yet recruiting2 trials

Lead sponsor

• Hoffmann-La Roche3 trials
• Radboud University Medical Center3 trials
• Amgen2 trials
• Boehringer Ingelheim2 trials
• Dutch Colorectal Cancer Group2 trials
• and 23 more

Running trials

• Not yet recruiting

  AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery

  NCT07883551· Catharina Ziekenhuis Eindhoven· Source

  Contact: Basiel Weyers, Medical Doctor

• Recruiting

  The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.

  NCT07234422· Phase 3· Netherlands Heart Institute· Source

  Contact: Jeroen Schaap, MD, PhD

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Dutch Society of Physicians for Pulmonology and Tuberculosis· Source

  Contact: F.T.A. van der Velde

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

  NCT06476119· The Netherlands Cancer Institute· Source

  Contact: J Heijns, MD

• Recruiting

  The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

  NCT06082492· Radboud University Medical Center· Source

  Contact: Research Longoncologie

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients

  NCT06092437· Zuyderland Medisch Centrum· Source

  Contact: Ijsbrand dr. Klip, MD, PhD

• Recruiting

  National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

  NCT05326620· PROspective Renal Cancer Cohort Foundation· Source

  Contact: H Westgeest

• Recruiting

  Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

  NCT05600127· Phase 2· Erasmus Medical Center· Source

  Contact: Westgeest

• Recruiting

  LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

  NCT05682482· Phase 3· M. Medici· Source

  Contact: Charlotte Krol, MD PhD

• Recruiting

  Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

  NCT05491200· Phase 4· Research Maatschap Cardiologen Rotterdam Zuid· Source

  Contact: Rohit Oemrawsingh, PhD

• Active, not recruiting

  A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

  NCT04825743· Phase 3· CeleCor Therapeutics· Source

• Recruiting

  Prospective Bladder Cancer Infrastructure (ProBCI)

  NCT04503577· Prospective Bladder Cancer Infrastructure Foundation· Source

  Contact: A. Richters, PhD

• Recruiting

  Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

  NCT06434896· UMC Utrecht· Source

  Contact: M. Streppel

• Active, not recruiting

  Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

  NCT03764553· Phase 2· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Active, not recruiting

  PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG

  NCT03805048· Amsterdam UMC, location VUmc· Source

• Recruiting

  S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System

  NCT03443999· Sahajanand Medical Technologies Limited· Source

  Contact: Vibhor Bhatia

• Active, not recruiting

  A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

  NCT02301286· Phase 3· Leiden University· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Dutch Colorectal Cancer Group· Source

  Contact: J. Schreinemakers

• Active, not recruiting

  Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

  NCT01792934· Radboud University Medical Center· Source

• Active, not recruiting

  Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

  NCT01558921· Phase 3· University Medical Center Groningen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Heart failure3 recruiting
• Bladder cancer2 recruiting
• Colorectal cancer2 recruiting
• Coronary artery disease2 recruiting
• Hypothyroidism1 recruiting
• Kidney cancer1 recruiting
• Mesothelioma1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery

  NCT05982184· Erasmus Medical Center· Source

• Completed

  A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device

  NCT05670587· Boehringer Ingelheim· Source

• Completed

  Upper Extremity Versus Lower Extremity Accessory Access Sites During Transcatheter Aortic Valve Implantation

  NCT05672823· Radboud University Medical Center· Source

• Completed

  Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

  NCT04931771· ECRI bv· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

  NCT03783429· Phase 4· University Medical Center Groningen· Source

• Completed

  Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

  NCT04657120· Leiden University Medical Center· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Hoffmann-La Roche· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· German CLL Study Group· Source

• Completed

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Phase 3· Dutch Colorectal Cancer Group· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source